

June 15, 1992




Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

VOLUME 52 • NO. 12 • PP 3255-3513

ISSN 0008-5472 • CNREA 8



AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Genetics of Cancer



November 4-8, 1992

Marriott Hilton Head Resort, Hilton Head, South Carolina

**Supported by a Generous Grant from
the General Motors Cancer Research Foundation**

CONFERENCE CO-CHAIRPERSONS

Webster K. Cavenee / La Jolla, CA
Raymond L. White / Salt Lake City, UT

SCIENTIFIC PROGRAM

Keynote Address

Robert A. Weinberg / Cambridge, MA

Inherited Cancer Genes

Bruce A.J. Ponder / Cambridge, England
Raymond L. White / Salt Lake City, UT
Frank McCormick / Emeryville, CA
Arnold J. Levine / Princeton, NJ
Webster K. Cavenee / La Jolla, CA

Genetic Mechanisms

Carmen Sapienza / La Jolla, CA
Carlo M. Croce / Philadelphia, PA
Neal G. Copeland / Frederick, MD

Molecular Genetics of Mitosis

George F. Vande Woude / Frederick, MD
Carol Greider / Cold Spring Harbor, NY
Andrew Murray / San Francisco, CA
David Beach / Cold Spring Harbor, NY
Erich A. Nigg / Lausanne, Switzerland

Genetic Instability

Geoffrey Wahl / San Diego, CA
C. Thomas Caskey / Houston, TX
Walton Fangman / Seattle, WA

Genetics and Cell Commitment

Stuart A. Aaronson / Bethesda, MD
Mariano Barbacid / Princeton, NJ
M. Geoffrey Rosenfeld / La Jolla, CA
David Anderson / Pasadena, CA
Leo Sachs / Rehovot, Israel

Animal Models

Mario Capecchi / Salt Lake City, UT
Douglas Hanahan / San Francisco, CA
Erwin Wagner / Vienna, Austria

Programmed Cell Death

Stanley J. Korsmeyer / St. Louis, MO
H. Robert Horvitz / Cambridge, MA
John T. Isaacs / Baltimore, MD
Peter Kramer / Heidelberg, Germany

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)

Application Deadline: August 10, 1992

AACR SPECIAL CONFERENCE IN CANCER RESEARCH
**Molecular and Biochemical Methods in
Cancer Epidemiology and Prevention -
The Path Between the Laboratory and the Population**

September 23-26, 1992
The Registry Resort, Naples, Florida



CONFERENCE CHAIRPERSON

David Schottenfeld / Ann Arbor, MI

PROGRAM COMMITTEE

Myron Essex / Boston, MA
Curtis C. Harris / Bethesda, MD
Thomas E. Moon / Tucson, AZ

Stephen S. Hecht / Valhalla, NY
Barbara S. Hulka / Chapel Hill, NC

Lewis H. Kuller / Pittsburgh, PA
Mortimer L. Mendelsohn / Livermore, CA
Paul A. Schulte / Cincinnati, OH

SCIENTIFIC PROGRAM

Keynote Addresses

Paul A. Schulte / Cincinnati, OH
Mortimer L. Mendelsohn / Livermore, CA
Curtis C. Harris / Bethesda, MD

Assessment of Exposure to Genotoxic Agents

Stephen S. Hecht / Valhalla, NY
Steven R. Tannenbaum / Cambridge, MA
Frederica Perera / New York, NY
John D. Groopman / Baltimore, MD
Gerald N. Wogan / Cambridge, MA

Biological Markers of Genetic Susceptibility

Louise C. Strong / Houston, TX
Bruce A.J. Ponder / Sutton, England
Mark Leppert / Salt Lake City, UT
Kenneth H. Buetow / Philadelphia, PA

Viral Agents

Myron Essex / Boston, MA
W. Thomas London / Philadelphia, PA
Wayne D. Lancaster / Detroit, MI
Mark Schiffman / Bethesda, MD
Nancy E. Mueller / Boston, MA

**Dietary Biomarkers in
Preventive Intervention Studies**

Thomas E. Moon / Tucson, AZ
John D. Potter / Minneapolis, MN
Gladys Block / Bethesda, MD
David P. Rose / Valhalla, NY

**Measurement of Endogenous Sex Steroid
Hormones in Breast and Prostate Neoplasia**

Lewis H. Kuller / Pittsburgh, PA
James Gutai / Detroit, MI
David Schottenfeld / Ann Arbor, MI

**Disorders of Immune Function in
Human Carcinogenesis**

Charles Rabkin / Bethesda, MD
Ian T. Magrath / Bethesda, MD
David T. Purtilo / Omaha, NE

**Evaluation of the Applications of
Biochemical and Molecular Markers in
Epidemiological Studies**

Barbara S. Hulka / Chapel Hill, NC
Neil E. Caporaso / Bethesda, MD
Nathaniel Rothman / Bethesda, MD
Arthur Schatzkin / Bethesda, MD
Mark Schiffman / Bethesda, MD


Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)

Application Deadline: June 15, 1992

COVER LEGEND



Cancer Research is pleased to salute Judah Folkman, M.D., the 1992 winner of the Wolf Award in medicine and the 3M Life Sciences Award from the Federation of American Societies for Experimental Biology. These prestigious prizes recognize a distinguished career marked by many contributions to medical science, extending from his student days to the present time.

While a student at Ohio State University, where he received the B.A. *cum laude* in 1953, he coauthored a paper with Dr. Robert Zollinger which described a new method of hepatectomy for liver cancer. As a student at Harvard Medical School, he worked in the laboratory of Dr. Robert Gross where he developed the first atrioventricular implantable pacemaker, for which he received the Boylston Medical Prize, the Soma Weiss Award, and the Borden Undergraduate Award. From 1957 to 1965, Dr. Folkman completed his internship and residency at Massachusetts General Hospital where he was Chief Resident in Surgery during 1964–1965; he served as a lieutenant in the United States Navy from 1960–1962. At the Naval Medical Center in Bethesda, MD, he first reported, with David Long, the use of silicone polymers for sustained release of drugs, which led to the development of Norplant, a now widely used implantable contraceptive. It was here that he began studies on tumor growth in isolated perfused organs, which led to his most significant discoveries of the dependency on angiogenesis for tumor growth and originated the field of angiogenesis research.

Dr. Folkman joined Harvard's Surgical Service in 1965 as Instructor and Associate Director of the Sears Surgical Laboratory of Boston City Hospital, and in 1967 he was promoted to Professor of Surgery at Harvard and to Surgeon-in-Chief at Children's Hospital Medical Center, becoming the Julia Dyckman Andrus Professor of

Pediatric Surgery in 1968. Before assuming full-time Chairmanship of the Surgery Department at Children's Hospital, he spent 6 months as Chief Resident in pediatric surgery under former Surgeon General C. Everett Koop at Philadelphia Children's Hospital. In 1981, after 14 years at Children's Hospital, he was appointed Professor of Anatomy and Cellular Biology at Harvard Medical School, when he gave up the Chairmanship of Surgery to devote his full time to research.

His discoveries on the mechanisms of angiogenesis opened up a field now pursued worldwide. His laboratory reported the first angiogenic molecule, the first angiogenesis inhibitor, and the angiogenesis dependency for tumor growth and developed almost all of the methodology for this field. In his laboratory, Michael Klagsbrun and Yuen Shing purified basic fibroblast growth factor, the first of seven angiogenic molecules which have been sequenced and cloned in other laboratories. He predicted the existence of natural angiogenesis inhibitors and discovered several families of angiostatic substances. The possibility of anti-angiogenic therapy is now being explored in several clinical trials.

In addition to the Wolf and FASEB awards, Dr. Folkman has received, among others, the Lila Gruber Award from the American Academy of Dermatology, 1974; the Simon Shubitz Cancer Prize from the University of Chicago, 1982; the Lucy Wortham James Award from the Society of Surgical Oncology, 1985; the G. H. A. Clowes Award from the AACR, 1985; the Sheen Award from the American College of Surgeons, 1989; election to the National Academy of Sciences and to its Institute of Medicine, 1990; the Gairdner Foundation International Award, 1991; and the Christopher Columbus Award from the National Institutes of Health, 1992.

Dr. Folkman is the author of 187 papers, among which the following summarize his major accomplishments: N. Weidner, J. Semple, W. Welch, and J. Folkman. Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. *N. Engl. J. Med.*, 324: 1–8, 1991; J. Folkman, Antiangiogenesis. *In: V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer*, pp. 743–753. Philadelphia: J. B. Lippincott and Company, 1991; J. Folkman and D. Hanaman. Expression of the angiogenic phenotype during development of murine and human cancer. *In: J. Burgee, T. Curran, E. Harlow, and F. McCormick (eds.), Origins of Human Cancer: A Comprehensive Review*, pp. 803–814. Plainview, NY: Cold Spring Harbor Laboratory, 1991; J. Folkman. Angiogenesis—retrospect and outlook. *In: R. Steiner, P. Weisz, and R. Langer (eds.), Angiogenesis Key Principles—Science—Technology—Medicine*, pp. 4–13. Basel: Birkhauser Verlag, 1992; J. Folkman. Tumor angiogenesis. *In: J. F. Holland, E. Frei, R. C. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine*, Ed. 3. Melbourne, PA: Lea & Febiger, in press, 1992.

Sidney Weinhouse